What sets QPharma apart as a CDMO, and which customer needs are we uniquely positioned to address?
QPharma combines long-standing pharmaceutical manufacturing experience with specialized capabilities in high-potency drug products and controlled-release polymer-based drug delivery systems. We can handle highly potent and cytotoxic API’s up to OEB 6 and have extensive expertise in co-extrusion, hot-melt extrusion and injection molding. Our capabilities also include aseptic filling of syringes, followed by automatic visual inspection, analytical testing and assembly into autoinjectors.
Our strength lies in supporting complex products that do not always fit within a conventional manufacturing platform. We work with customers from early formulation and process development through clinical supply, scale-up and commercial manufacturing. This integrated approach helps reduce development risk and ensures that manufacturability and scalability are considered from the beginning.
Together, these capabilities allow us to support both emerging biotech companies and established pharmaceutical companies with specialized development and manufacturing needs.
What role does QPharma play in the Medicon Valley Alliance life science ecosystem, and how can we contribute to innovation in the region?
QPharma’s goal is to bridge the gap between scientific innovation and a robust, scalable and commercially viable drug product. By engaging early, we can integrate formulation, analytical development, process design, regulatory requirements and GMP manufacturing, helping customers reduce development risk and accelerate the path to clinical trials and commercialization.
Through closer collaboration with companies, academia and other life science partners across the region, we can contribute with practical manufacturing expertise, strengthen promising projects and help translate local innovation into treatments that reach patients. QPharma has an established development and manufacturing site in Malmö, giving companies in the Medicon Valley Alliance region access to local CDMO capabilities.
QPharma supports drug developers in turning a product concept into a scalable manufacturing process. Our capabilities include formulation and process development, analytical support, clinical supply and commercial GMP manufacturing.
By working more closely with regional companies and universities, we can provide practical development and manufacturing expertise early in projects and help move products towards clinical trials and commercial supply.
Where does QPharma see the greatest opportunities for future growth and innovation?
We see significant opportunities in advanced drug delivery, particularly for high-potent compounds and controlled-release polymer-based products. As drug substances become increasingly potent and complex, pharmaceutical companies need partners that can combine specialized containment with formulation, process development and scalable manufacturing.
Technologies such as hot-melt extrusion, implants and other polymer-based dosage forms can improve bioavailability, provide controlled or targeted drug release and potentially improve the patient experience. We also see continued demand for integrated aseptic fill-and-finish services, including prefilled syringes and autoinjectors.
Our focus is therefore on strengthening our ability to support customers throughout the pharmaceutical journey, from initial feasibility and clinical development to reliable commercial supply, while continuing to develop solutions for increasingly complex products.